Results 81 to 90 of about 12,443,450 (160)

Fibrinogen catabolism in patients with type II and type IV hyperlipidemia. Effect of dietary and clofibrate treatment on laboratory findings.

, 1981
Fibrinogen catabolism was studied by plasma fibrinogen chromatography and other methods in 99 subjects with hyperlipoproteinemia Types IIa, IIb, and IV, and in 24 control subjects with normal blood lipid values.
G Schonfeld, A Fletcher, N Alkjaersig, J Witztum   +3 more
core   +1 more source

Distribution of Apolipoprotein(a) in the Plasma from Patients with Lipoprotein Lipase Deficiency and with Type Ill Hyperlipoproteinemia No Evidence for a Triglyceride-rich Precursor of Lipoprotein (a)

, 2014
Lipoprotein(a) consists of a low-density lipoprotein containing apolipoprotein (apo) B-100 and of the genetically polymorphic apo(a). It is not known where and how lipoprotein(a) is assembled and whether there exists a precursor for lipoprotein(a).

core  

Arteriosclerotic carotid lesions in hyperlipoproteinemia.

, 1986
An ultrasonographic study was performed in 187 hyperlipoproteinemia patients to evaluate the incidence of atheromatous lesions in the extracranial carotid tract.
MANNARINO, Elmo, Susta A, Tazza D, Pistola L, Senin U.   +4 more
core  

CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia

, 2017
Metabolic inflammation is closely associated with hyperlipidemia and cardiovascular disease. However, the underlying mechanisms are not fully understood. The current study established that cAMP-responsive-element-binding protein H (CREBH), an acute-phase
Song, Yongyan, Zhao, Miaoyun, Xiao Cheng, Rituraj Khound, Miaoyun Zhao, Zhang, Kezhong, Khound, Rituraj, Yongyan Song, Qiaozhu Su, Shen, Jing, Kezhong Zhang, Jing Shen, Cheng, Xiao, Su, Qiaozhu   +13 more
core   +1 more source

Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.

, 1984
The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. However, in the majority of patients treated with one
D L Sprecher, H B Brewer, E Bou, A M Pikus, K R Bailey, R E Gregg, J M Hoeg, L A Zech, J K Susser, M B Maher   +9 more
core   +1 more source

Gemfibrozil Treatment of Combined Hyperlipoproteinemia

, 1996
Hypertriglyceridemia is linked to impaired fibrinolytic function, and lipid-lowering treatment with fibric acid derivatives could hypothetically improve fibrinolysis in this condition.
Paul Hjemdahl, Björn Wiman, Bo Angelin, Anders Bröijersen, Mats Eriksson, Broijersen, A, Eriksson, M,, Wiman, B, Angelin, B,, Hjemdahl, P,   +9 more
core   +1 more source

Predictors of Family Recruitment in a Program of Genetic Cascade Screening for Familial Hypercholesterolemia

Arquivos Brasileiros de Cardiologia
Maria Cristina de Oliveira Izar, Francisco Antonio Helfenstein Fonseca   +1 more
doaj   +1 more source

[Relationship between blood fibrinogen and plasma lipoproteins in patients with hypercholesterolemia].

, 1994
OBJECTIVE: Subjects with risk factors of atherosclerotic cardiovascular disease showed frequently high plasma levels of fibrinogen. Nevertheless, the relationship between hyperfibrinogenemia and atherosclerotic risk factors is not yet well known.
S. Massafra, ALESSANDRI, Cesare, C. Camcrini, CORDOVA, Corrado, M. Vieri, BASILI, Stefania, D. :. Cara   +6 more
core  

Clinical utility gene card for: Hyperlipoproteinemia, TYPE II [PDF]

European Journal of Human Genetics, 2013
Kassner, U., Wühle-Demuth, M., Missala, I., Humphries, S., Steinhagen-Thiessen, E., Demuth, I.   +5 more
openaire   +3 more sources

Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia

, 1991
After 15 weeks of simvastatin therapy (20 mg/day), low density lipoprotein particle size in sera of 16 patients with type IIb hyperlipoproteinemia increased significantly from 233 ± 5.0 Å to 237 ± 7.0 Å (P < 0.05), analyzed by 2–16% polyacrylamide ...
Hooft, F.M. van 't, Gevers Leuven, J.A., Zhao, S.P., hollar, L., Smelt, A.H.M., Laarse, A. van der   +5 more
core